Correction of Chloride Transport and Mislocalization of CFTR Protein by Vardenafil in the Gastrointestinal Tract of Cystic Fibrosis Mice

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Dhooghe, Barbara ^a   Noël, Sabrina ^a   Bouzin, Caroline ^a   Behets Wydemans, Gaëtane ^a   Leal, Teresinha ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CHLORIDE TRANSPORT; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG MECHANISM; FEMALE; GASTROINTESTINAL TRACT; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTESTINE CELL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SINGLE DRUG DOSE; SODIUM TRANSPORT;

ANIMALS; CATIONS, MONOVALENT; CELL POLARITY; CHLORIDES; COLON; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; GENE EXPRESSION; HUMANS; IMIDAZOLES; INTESTINAL MUCOSA; ION TRANSPORT; MALE; MEMBRANE POTENTIALS; MICE; MICE, INBRED CFTR; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; SODIUM; SULFONES; TRIAZINES;

EID: 84886248189     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077314     Document Type: Article

References (55)

1. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, et al. (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245: 1073-1080.
2. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073.
3. Stutts MJ, Rossier BC, Boucher RC, (1997) Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics. J Biol Chem 272: 1437-1440.
4. Ismailov II, Awayda MS, Jovov B, Berdiev BK, Fuller CM, et al. (1996) Regulation of epithelial sodium channels by the cystic fibrosis transmembrane conductance regulator. J Biol Chem 271: 4725-4732.
5. Amaral MD, Farinha CM, (2013) Rescuing mutant CFTR: a multi-task approach to a better outcome in treating Cystic Fibrosis. Curr Pharm Des 19: 3497-3508.
6. Ward CL, Omura S, Kopito RR, (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83: 121-127.
7. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, et al. (2012) Results of a phase IIa study of VX-809, an investigational CFTR corrrector compound, in subjects with cystic fibrosis homozygous for the F508del- CFTR mutation. Thorax 67: 12-18.
8. Rowe SM, Verkman AS (2013) Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 3.
9. Birault V, Solari R, Hanrahan J, Thomas DY, (2013) Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis. Curr Opin Chem Biol 17: 353-360.
10. Merk D, Schubert-Zsilavecz M, (2013) Repairing mutated proteins-development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator. Expert Opin Drug Discov 8: 691-708.
11. Leonard A, Lebecque P, Dingemanse J, Leal T, (2012) A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cyst Fibros 11: 231-236.
12. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, et al. (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354: 526-528.
13. Heda GD, Tanwani M, Marino CR, (2001) The delta F508 mutation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am J Physiol Cell Physiol 280: 166-174.
14. Jouret F, Bernard A, Hermans C, Dom G, Terryn S, et al. (2007) Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney. J Am Soc Nephrol 18: 707-718.
15. Raggi C, Fujiwara K, Leal T, Jouret F, Devuyst O, et al. (2011) Decreased renal accumulation of aminoglycoside reflects defective receptor-mediated endocytosis in cystic fibrosis and Dent's disease. Pflugers Arch 462: 851-860.
16. Swiatecka-Urban A, Brown A, Moreau-Marquis S, Renuka J, Coutermarsh B, et al. (2005) The short apical membrane half-life of rescued {Delta}F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of {Delta}F508-CFTR in polarized human airway epithelial cells. J Biol Chem 280: 36762-36772.
17. Moniz S, Sousa M, Moraes BJ, Mendes AI, Palma M, et al. (2013) HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR. ACS Chem Biol 8: 432-442.
18. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, et al. (2010) Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol 12: 863-875.
19. Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, et al. (2013) Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol 9: 444-454.
20. Pier GB, (2012) The challenges and promises of new therapies for cystic fibrosis. J Exp Med 209: 1235-1239.
21. Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, et al. (2012) Progress in cystic fibrosis and the CF therapeutics development network. Thorax 67: 882-890.
22. Chen EY, Bartlett MC, Clarke DM, (2000) Cystic fibrosis transmembrane conductance regulator has an altered structure when its maturation is inhibited. Biochemistry 39: 3797-3803.
23. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, et al. (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: 1991-2003.
24. Middleton PG, Geddes DM, Alton EWFW, (1994) Protocols for in vivo measurements of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 7: 2050-2056.
25. Knowles MR, Paradiso AM, Boucher RC, (1995) In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 6: 445-455.
26. Sermet-Gaudelus I, De Boeck K, Casimir GJ, Vermeulen F, Leal T, et al. (2010) Ataluren (PTC124) Induces CFTR Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis. Am J Respir Crit Care Med 182: 1262-1272.
27. Boucher RC, (2007) Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 58: 157-170.
28. Wilschanski M, Durie PR, (2007) Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut 56: 1153-1163.
29. Anderson MP, Rich DP, Gregory RJ, Smith AE, Welsh MJ, (1991) Generation of cAMP activated chloride currents by expression of CFTR. Science 251: 679-682.
30. Gadsby DC, Nairn AC (1999) Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol Rev 79 (1 Suppl): S77-S107.
31. Welsh MJ, Smith PL, Fromm M, Frizzell RA, (1982) Crypts are the site of intestinal fluid and electrolyte secretion. Science 218: 1219-1221.
32. Rotella DP, (2002) Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 1: 674-682.
33. Dormer RL, Harris CM, Clark Z, Pereira MM, Doull IJ, et al. (2005) Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 60: 55-59.
34. Lubamba B, Lecourt H, Lebacq J, Lebecque P, De Jonge H, et al. (2008) Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 177: 506-515.
35. Lubamba B, Lebacq J, Reychler G, Marbaix E, Wallemacq P, et al. (2011) Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice. Eur Respir J 37: 72-78.
36. van Doorninck JH, French PJ, Verbeek E, Peters RH, Morreau H, et al. (1995) A mouse model for the cystic fibrosis delta F508 mutation. EMBO J 14: 4403-4411.
37. Leonard A, Lubamba B, Dhooghe B, Noel S, Wallemacq P, et al. (2012) Comparative variability of nasal potential difference measurements in human and mice. Open J Respir Dis 2: 43-56.
38. Lubamba B, Lebacq J, Lebecque P, Vanbever R, Leonard A, et al. (2009) Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 179: 1022-1028.
39. Carvalho-Oliveira I, Efthymiadou A, Malhó R, Nogueira P, Tzetis M, et al. (2004) CFTR localization in native airway cells and cell lines expressing wild-type or F508del-CFTR by a panel of different antibodies. J Histochem Cytochem 52: 193-203.
40. Lubamba B, Huaux F, Lebacq J, Marbaix E, Dhooghe B, et al. (2012) Immunomodulatory activity of vardenafil on induced lung inflammation in cystic fibrosis mice. J Cyst Fibros 11: 266-273.
41. Huaux F, Noel S, Dhooghe B, Panin N, Lo Re S, et al. (2013) Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis. PLoS One 8: e64341.
42. Hug MJ, Derichs N, Bronsveld I, Clancy JP, (2011) Measurement of ion transport function in rectal biopsies. Methods Mol Biol 741: 87-107.
43. Weiner SA, Caputo C, Bruscia E, Ferreira EC, Price JE, et al. (2008) Rectal potential difference and the functional expression of CFTR in the gastrointestinal epithelia in cystic fibrosis mouse models. Pediatr Res 63: 73-78.
44. Grubb BR, Gabriel SE, (1997) Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis. Am J Physiol 273: G258-G266.
45. Chao AC, de Sauvage FJ, Dong YJ, Wagner JA, Goeddel DV, et al. (1994) Activation of intestinal CFTR Cl- channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J 13: 1065-1072.
46. Kelley TJ, Cotton CU, Drumm ML, (1998) Regulation of amiloride-sensitive sodium absorption in murine airway epithelium by C-type natriuretic peptide. Am J Physiol 274: L990-L996.
47. Cobb BR, Fan L, Kovacs TE, Sorscher EJ, Clancy JP, (2003) Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol 29: 410-418.
48. Al-Nakkash L, Hwang TC, (1999) Activation of wild-type and deltaF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and-independent mechanisms. Pflugers Arch 437: 553-561.
49. Ameen N, Alexis J, Salas P, (2000) Cellular localization of the cystic fibrosis transmembrane conductance regulator in mouse intestinal tract. Histochem Cell Biol 114: 69-75.
50. Poschet JF, Timmins GS, Taylor-Cousar JL, Ornatowski W, Fazio J, et al. (2007) Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 293: L712-L719.
51. Golin-Bisello F, Bradbury N, Ameen N, (2005) STa and cGMP stimulate CFTR translocation to the surface of villus enterocytes in rat jejunum and is regulated by protein kinase G. Am J Physiol Cell Physiol. 289: C708-C716.
52. Leier G, Bangel-Ruland N, Sobczak K, Knieper Y, Weber WM, (2012) Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease. Cell Physiol Biochem 29: 775-790.
53. Legssyer R, Huaux F, Lebacq J, Delos M, Marbaix E, et al. (2006) Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res 7: 134.
54. Mendes F, Doucet L, Hinzpeter A, Férec C, Lipecka J, et al. (2004) Immunohistochemistry of CFTR in native tissues and primary epithelial cell. J Cyst Fibros 3Suppl 2: 37-41.
55. Mendes F, Farinha CM, Roxo-Rosa M, Fanen P, Edelman A, et al. (2004) Antibodies for CFTR studies. J Cyst Fibros 3Suppl 2: 69-72.